Evidence map›Paper›PMID 32273779›Full record

ArticleClinical pharmacology : advances and applications2020

Determination of the Permeation and Penetration of Flurbiprofen into Cadaveric Human Pharynx Tissue.

Rob Turner, Sean Robert Wevrett, Suzanne Edmunds, Marc B Brown, Robert Atkinson, Oluwajoba Adegoke, Anuradha Kulasekaran, Tim Shea

Open access · goldAbstract read
In one paragraph

Article in Clinical pharmacology : advances and applications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Rob TurnerMedPharm Ltd, Surrey Research Park, Guildford, UK.
Sean Robert WevrettMedPharm Ltd, Surrey Research Park, Guildford, UK.ORCID 0000-0003-4463-9052
Suzanne EdmundsMedPharm Ltd, Surrey Research Park, Guildford, UK.ORCID 0000-0001-9275-8203
Marc B BrownMedPharm Ltd, Surrey Research Park, Guildford, UK.
Robert AtkinsonMedical Science, Reckitt Benckiser, Hull, UK.
Oluwajoba AdegokeMedical Science, Reckitt Benckiser, Hull, UK.
Anuradha KulasekaranMedical Affairs, Reckitt Benckiser, Slough, UK.
Tim SheaMedical Science, Reckitt Benckiser, Parsippany, NJ, USA.ORCID 0000-0001-7043-1621
MedPharm (United Kingdom) · GBReckitt Benckiser (United Kingdom) · GBReckitt Benckiser (United States) · USUniversity of Hertfordshire · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveFlurbiprofen 8.75 mg spray and lozenge have a rapid onset of action for sore throat relief, suggesting local action, although tissue penetration and the mechanism of local relief have not been determined. This investigation aimed to quantify the permeation and penetration of flurbiprofen, applied as local pharmaceutical forms, into full-thickness cadaveric human mucosal pharynx tissue, representing the clinical scenario as far as possible.

methodsA validated high-performance liquid chromatography method quantified the permeation and penetration of flurbiprofen (spray and lozenge formulations) into human cadaveric pharynx tissue using a micro Franz cell model mimicking physiological and anatomical conditions. Full-thickness mucosal pharynx tissue, consisting of oral epithelium, basement membrane, and lamina propria, was utilized to imitate the in vivo setting. Flurbiprofen was analyzed on the surface of the pharynx tissue, within the pharynx tissue and in receiver fluid, over 60 mins.

resultsFlurbiprofen was detected in receiver fluid from 10 mins following spray application and was quantifiable from 20 mins. Flurbiprofen from lozenge was detected from 10 mins and was above the limit of quantitation in receiver fluid from 40 mins. Flurbiprofen recovered from the surface of the pharynx tissue was 24.45% and 8.48% of applied dose for spray and lozenge, respectively. Flurbiprofen recovered within pharynx tissue was 46.50% and 54.65% of applied dose for spray and lozenge, respectively. For flurbiprofen lozenge, recovery within pharynx tissue was 6-fold higher relative to recovery from the pharynx tissue surface.

conclusionFlurbiprofen from spray and lozenge formulations penetrated human cadaveric pharynx tissue, indicating that flurbiprofen can reach all layers of the pharynx mucosal tissue, including the underlying lamina propria, which contains blood vessels and nerve fibers that contribute to pain during sore throat. This suggests that flurbiprofen may have a local mechanism of action for sore throat, although this has yet to be determined.

Indexed as

chromatographyflurbiprofenFranz diffusion cellhigh-pressure liquidpharynx

Identifiers

PMID32273779
PMCPMC7102892
OpenAlexW3012939828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.